Enterobacteriaceae Infections
Conditions
Brief summary
This is an open-label dynamic whole-body PET/CT (positron emission tomography/computed tomography) study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 18F-FDS in healthy volunteers and patients with suspected infection. A single dose of nearly 370 MBq 18F-FDS will be intravenously injected into healthy volunteers and patients with suspected infection. Visual and semiquantitative method will be used to assess the PET/CT images. Changes of blood pressure, pulse, respiration, temperature, routine blood and urine tests, serum alanine aminotransferase, albumin, and creatinine, and any adverse events will be collected from the volunteers. Adverse events will also be observed in the patients.
Detailed description
In clinical microbiology, pathogenic enterobacteriaceae are differentiated from other organisms by selectively metabolizing sorbitol. They exclusively express the enzyme sorbitol-6-phosphate dehydrogenase, which is the enzyme responsible for initiating sorbitol metabolism. 2-\[18F\]-fluorodeoxysorbitol (18F-FDS) is a positron-emitting analog of sorbitol. The substitution of the hydroxyl group by fluorine at the C-2 position, however, completely abrogates the recognition by mammalian sorbitol dehydrogenase.18F-FDS could be a suitable probe to selectively label and tomographically image enterobacteriaceae in vivo. For further interests in clinical translation of 18F-FDS, an open-label dynamic whole-body PET/CT study was designed to investigate radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 18F-FDS in healthy volunteers and patients with suspected infection. A single dose of nearly 370 MBq 18F-FDS will be intravenously injected into healthy volunteers and patients with suspected infection. Visual and semiquantitative method will be used to assess the PET/CT images. Changes of blood pressure, pulse, respiration, temperature, routine blood and urine tests, serum alanine aminotransferase, albumin, and creatinine, and any adverse events will be collected from the volunteers. Adverse events will also be observed in the patients.
Interventions
DRUG18F-FDS
18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers: o Males and females, ≥18 years old * Infectious patients: * Males and females, ≥18 years old * Characteristic clinical signs, symptoms and laboratory tests suggesting the diagnosis of infectious disease. * The diagnosis of infection is based on The Centres for Disease Control and Prevention (CDC) criteria for diagnosing infection. They rely on a combination of clinical, radiological, operative, microbiological, and histological findings, in addition to results of other laboratory tests, such as the white blood cell count, erythrocyte sedimentation rate, and C reactive protein value.
Exclusion criteria
* Females planning to bear a child recently or with childbearing potential * Renal function: serum creatinine \>3.0 mg/dL (270 μM/L) * Liver function: any hepatic enzyme level more than 5 times upper limit of normal. * Known severe allergy or hypersensitivity to IV radiographic contrast. * Patients not able to enter the bore of the PET/CT scanner. * Inability to lie still for the entire imaging time because of cough, pain, etc. * Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. * Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the Investigator, may significantly interfere with study compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual and semiquantitative assessment of lesions and biodistribution | One year | Visual analysis will be performed by consensus reading by at least 3 experienced nuclear medicine physician. The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake values (SUVs) of tumor and organs will be measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulse | 24 hours | Pulse will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment. |
| Respiration frequency | 24 hours | Respiration frequency will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment. |
| Temperature | 24 hours | Temperature will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment. |
| Routine blood test | 24 hours | Routine blood test of healthy volunteers will be measured at two time points: right before injection and 24 hours after treatment. |
| Blood pressure | 24 hours | Blood pressure of healthy volunteers will be measured at three time points: right before injection, after scanning, and 24 hours after treatment. |
| Serum alanine aminotransferase | 24 hours | Serum alanine aminotransferase of healthy volunteers will be measured at two time points: right before injection and 24 hours after treatment. |
| Serum albumin | 24 hours | Serum albumin of healthy volunteers will be measured at two time points: right before injection and 24 hours after treatment. |
| Serum creatinine | 24 hours | Serum creatinine of healthy volunteers will be measured at two time points: right before injection and 24 hours after treatment. |
| Adverse events collection | 5 days | Adverse events within 5 days after the injection and scanning of healthy volunteers and patients will be followed and assessed. |
| Routine urine test | 24 hours | Routine urine test of healthy volunteers will be measured at two time points: right before injection and 24 hours after treatment. |
Countries
China
Contacts
Primary ContactLi Fang, MD
Backup ContactZhu Zhaohui, MD, PhD
Outcome results
None listed